Expertise in
28
conditions

Dr. Daniel W. Weed

Radiation Oncology
Community Hospital East
1500 N Ritter Ave, 
Indianapolis, IN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
28
conditions
Community Hospital East
1500 N Ritter Ave, 
Indianapolis, IN 

Overview

Daniel Weed is a Radiation Oncologist practicing medicine in Indianapolis, Indiana.

Dr. Weed is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Small Cell Lung Cancer (SCLC), and Posterior Fossa Tumor.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 7 clinical trials. Dr. Weed is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in NV

Hospital Affiliations

Community Howard Regional Health Inc.
Community Hospital North
Community Hospital Of Anderson And Madison County
Hendricks Regional Health
Community Hospital East

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
MDwise
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Community Hospital East
1500 N Ritter Ave, Indianapolis, IN 46219
Other Locations
Community Howard Regional Health
3500 S Lafountain St, Kokomo, IN 46902

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
Enrollment Status: Recruiting
Publish Date: June 09, 2026
Intervention Type: Radiation, Procedure, Drug
Study Drug: Memantine
Study Phase: Phase 3
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Temozolomide
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Radiation, Other
Study Phase: Phase 3
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial
Enrollment Status: Active_not_recruiting
Publish Date: June 08, 2026
Intervention Type: Radiation, Drug
Study Drugs: Docetaxel, Gemcitabine, Pemetrexed Disodium, Erlotinib Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
Enrollment Status: Suspended
Publish Date: March 05, 2026
Intervention Type: Other, Radiation
Study Phase: Phase 2/Phase 3
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

1 Total Publications

Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial.
Adding Metastasis-Directed Therapy to Standard-of-Care Systemic Therapy for Oligometastatic Breast Cancer (EXTEND): A Multicenter, Randomized Phase 2 Trial.
Journal: International journal of radiation oncology, biology, physics
Published: May 23, 2024
Similar Doctors
Expertise in
17
conditions
Dr. Tim Lautenschlaeger
Radiation Oncology
Expertise in
17
conditions
Dr. Tim Lautenschlaeger
Radiation Oncology
Referral may be required

IU Health Methodist Hospital

1701 Senate Blvd, 
Indianapolis, IN 
 (4.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tim Lautenschlaeger is a Radiation Oncologist practicing medicine in Indianapolis, Indiana. Dr. Lautenschlaeger is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Posterior Fossa Tumor. Dr. Lautenschlaeger is currently accepting new patients.

Expertise in
29
conditions
Dr. Kevin R. Shiue
Radiation Oncology
Expertise in
29
conditions
Dr. Kevin R. Shiue
Radiation Oncology
Referral may be required

IU Health Methodist Hospital

1701 Senate Blvd, 
Indianapolis, IN 
 (4.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kevin Shiue is a Radiation Oncologist practicing medicine in Indianapolis, Indiana. Dr. Shiue is highly rated in 29 conditions, according to our data. His clinical expertise encompasses Atypical Teratoid Rhabdoid Tumor (ATRT), Brain Tumor, Gliosarcoma, and Meningioma. Dr. Shiue is currently accepting new patients.

Expertise in
40
conditions
Dr. Christopher A. Leagre
Radiation Oncology
Expertise in
40
conditions
Dr. Christopher A. Leagre
Radiation Oncology
Referral may be required

Cancer Care Group

6100 W 96th St, Ste 125, 
Indianapolis, IN 
 (13.8 miles away)
317-715-1800
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Leagre, MD, is an independent radiation oncologist at Ascension St. Vincent in Indianapolis, Indiana. He delivers radiotherapy such as internal and external beam radiation therapy, brachytherapy and systemic radiation therapy. Dr. Leagre is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Radiation Induced Meningioma, Meningioma, Intraductal Papilloma, and Astrocytoma. Dr. Leagre is board certified in The American Board Of Radiology - Radiation Oncology. Dr. Leagre is currently accepting new patients.

Frequently Asked Questions about Dr. Daniel W. Weed

How do I make an appointment with Dr. Daniel W. Weed?

You can book an appointment with Dr. Daniel W. Weed by calling their office at 317-355-5347. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel W. Weed a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel W. Weed is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel W. Weed specialize in?

While Dr. Daniel W. Weed is a Radiation Oncology, they have specific expertise in Lung Cancer, Pleuropulmonary Blastoma, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Daniel W. Weed participate in research or clinical trials?

Yes. Dr. Daniel W. Weed has published 1 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Daniel W. Weed's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel W. Weed accept my insurance?

Dr. Daniel W. Weed accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 317-355-5347 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Weed's expertise for a condition
ConditionClose
    View All 22 Advanced Conditions
    View All 54 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile